ArticleCancer immunology research2021
Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Macrophage Trogocytosis of Tumor Cells Drives the Immunosuppression of Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immune surveillance interrupted: how cancer exploits trogocytosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- From pathogenesis to therapeutic targeting: new insight into TAM receptors in rheumatoid arthritis.Cell & bioscience · 2025Review
- Molecular Dynamics of Trogocytosis and Other Contact-Dependent Cell Trafficking Mechanisms in Tumor Pathogenesis.Cancers · 2025Review
- Natural killer cell-based immunotherapy for cancer.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression.PLoS biology · 2025Review
- Commentary: is trogocytosis relevant for chimeric antigen receptor-T cells?The oncologist · 2025Article
- Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non-Viral CAR-NK Cell Engineering.Cell proliferation · 2025Review
- Distinct TYRO3 and PROS1 expression levels contribute to preeclampsia pathogenesis.Histochemistry and cell biology · 2025Article
- Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy.Frontiers in pharmacology · 2025Review
- Trogocytosis at the crossroad of cancer and immunity: mechanisms, implications and therapeutic perspectives.Frontiers in cell and developmental biology · 2025Review
- Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape.Cell communication and signaling : CCS · 2024Review
- Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility.International journal of molecular sciences · 2024Review
- CTLA-4 tail fusion enhances CAR-T antitumor immunity.Nature immunology · 2023Article
- Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Viral- and tumor-reactive natural killer cells.Seminars in immunology · 2023Review
- TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment.Journal for immunotherapy of cancer · 2023Article
- NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells.Frontiers in immunology · 2023Article
- Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Ting LuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.
Rui MaDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.
Zhenlong LiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.
Anthony G MansourDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.
Kun-Yu TengDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.
Li ChenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.
Jianying ZhangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Los Angeles, California.
Tasha BarrDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.ORCID 0000-0003-1404-7830
Michael A CaligiuriDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California. mcaligiuri@coh.org jiayu@coh.org.ORCID 0000-0002-4095-3020
Jianhua YuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California. mcaligiuri@coh.org jiayu@coh.org.
City Of Hope National Medical Center · US
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MThe Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI KEITH LLOYD LIGON · 2013 to 2026
$26.0MHuman natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3MIL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5MTargeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaR01CA265095 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BUDDE, LIHUA ELIZABETH, CALIGIURI, MICHAEL A · 2021 to 2025
$2.4MCharacterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK CellsR01CA247550 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2020 to 2024
$2.2MElucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1MDNA Damage Response and Oncogenic SignalingT32CA186895 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BINGHUI SHEN, Jeremy Michael Stark · 2016 to 2026
$2.1MOvercoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9MCancer Metabolism Training ProgramT32CA221709 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI David K. Ann, Victoria L. Seewaldt · 2018 to 2026
$1.8MPhase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint InhibitorsR01CA266457 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALONA, MIGUEL A, YU, JIANHUA · 2022 to 2025
$1.8MIL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4MNCI NIH HHS P01 CA163205NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA068458NCI NIH HHS R01 CA247550NCI NIH HHS R01 CA265095NCI NIH HHS R01 CA266457NCI NIH HHS R21 CA223400NCI NIH HHS R35 CA210087NCI NIH HHS R37 CA068458NCI NIH HHS T32 CA186895NCI NIH HHS T32 CA221709NIAID NIH HHS R01 AI129582NINDS NIH HHS R01 NS106170
Abstract
Trogocytosis is a fast, cell-cell contact-dependent uptake of membrane patches and associated molecules by one cell from another. Here, we report our investigation of trogocytosis of TYRO3, a cell membrane protein, from tumor target cells to natural killer (NK) cells and the associated functional consequences for NK cells. We found that although NK cells did not express endogenous TYRO3 on the cell surface, activated NK cells rapidly acquired TYRO3 from tumor cells via trogocytosis
Indexed as
Cytotoxicity, ImmunologicTrogocytosisAnimalsCell ProliferationHumansK562 CellsKiller Cells, NaturalMiceReceptor Protein-Tyrosine KinasesReceptors, Chimeric AntigenXenograft Model Antitumor AssaysReceptor Protein-Tyrosine KinasesReceptors, Chimeric AntigenTYRO3 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.